miR-106b is a novel target to promote muscle regeneration and restore satellite stem cell function in injured Duchenne dystrophic muscle: Molecular Therapy - Nucleic Acids
Genetics: An introduction to Risk Analysis in X-linked Recessive Disorders
Frontiers | Current Pharmacological Strategies for Duchenne Muscular Dystrophy
PDF) Polygenic transcriptome risk scores (PTRS) can improve portability of polygenic risk scores across ancestries
ASCVD Risk Estimator +
Genetics: An introduction to Risk Analysis in X-linked Recessive Disorders
Carrier assessment for mothers and sisters of isolated Duchenne dystrophy cases | Semantic Scholar
Carrier assessment for mothers and sisters of isolated Duchenne dystrophy cases | Semantic Scholar
Current Clinical Applications of In Vivo Gene Therapy with AAVs - ScienceDirect
Genetics: An introduction to Risk Analysis in X-linked Recessive Disorders
Risk calculation under the condition of germline mosaicism. | Download Table
Easy calculations of lod scores and genetic risks on small computers. | Semantic Scholar
human genetic disease - Estimating probability: Bayes's theorem | Britannica
Genes | Free Full-Text | Obstructive Sleep Apnea and Dementia-Common Gene Associations through Network-Based Identification of Common Driver Genes
Frontiers | Sudden Cardiac Death—A New Insight Into Potentially Fatal Genetic Markers
An X-linked recessive pedigree. Nathan is the only member of the family... | Download Scientific Diagram
mRNA-mediated delivery of gene editing tools to human primary muscle stem cells: Molecular Therapy - Nucleic Acids
Risk Calculator
Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases | Nature Communications
Germinal mosaicism and risk calculation in X-linked diseases. - Abstract - Europe PMC
Carrier assessment for mothers and sisters of isolated Duchenne dystrophy cases | Semantic Scholar
Exons 45–55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene: Molecular Therapy
Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study - The Lancet Neurology
